← Back to Search

Monoclonal Antibodies

Depemokimab for Asthma (SWIFT-1 Trial)

Phase 3
Waitlist Available
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) and week 52
Awards & highlights

SWIFT-1 Trial Summary

This trial will test whether GSK3511294 is effective and safe in people with severe uncontrolled asthma that is characterized by high levels of eosinophils.

SWIFT-1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) and week 52
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 1) and week 52 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Annualized rate of clinically significant exacerbations over 52 weeks
Secondary outcome measures
Annualized rate of exacerbations requiring hospitalization and/or Emergency department (ED) visit over 52 weeks
Change from Baseline in Asthma Control Questionnaire-5 (ACQ-5) score at Week 52 (scores on a scale)
Change from Baseline in Saint (St.) George's Respiratory Questionnaire (SGRQ) total score at Week 52 (scores on a scale)
+1 more

SWIFT-1 Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Participants receiving GSK3511294 (Depemokimab)Experimental Treatment1 Intervention
Participants will be administered GSK3511294 (Depemokimab) along with SoC.
Group II: Participants receiving placeboPlacebo Group1 Intervention
Participants will be administered matching placebo along with SoC.

Find a Location

Who is running the clinical trial?

Iqvia Pty LtdIndustry Sponsor
106 Previous Clinical Trials
169,613 Total Patients Enrolled
4 Trials studying Asthma
2,764 Patients Enrolled for Asthma
GlaxoSmithKlineLead Sponsor
4,742 Previous Clinical Trials
8,065,966 Total Patients Enrolled
293 Trials studying Asthma
414,922 Patients Enrolled for Asthma
GSK Clinical TrialsStudy DirectorGlaxoSmithKline
3,593 Previous Clinical Trials
6,142,958 Total Patients Enrolled
229 Trials studying Asthma
401,849 Patients Enrolled for Asthma

Media Library

GSK3511294 (Depemokimab) (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04719832 — Phase 3
Asthma Research Study Groups: Participants receiving GSK3511294 (Depemokimab), Participants receiving placebo
Asthma Clinical Trial 2023: GSK3511294 (Depemokimab) Highlights & Side Effects. Trial Name: NCT04719832 — Phase 3
GSK3511294 (Depemokimab) (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04719832 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many test subjects are a part of this experiment?

"Yes, the information on clinicaltrials.gov suggests that this trial is actively searching for participants. The trial was initially posted on 3/17/2021 and was most recently updated on 10/18/2022. The study is enrolling 375 patients between 33 locations."

Answered by AI

What is the margin of safety for GSK3511294 (Depemokimab)?

"GSK3511294 (Depemokimab) has been rated as a 3 in terms of safety. This is due to being a Phase 3 trial, which provides some evidence of efficacy as well as multiple rounds of data supporting its safety."

Answered by AI

Are we still enrolling individuals for this clinical research project?

"The website clinicaltrials.gov has the most recent information on this trial, which is actively recruiting patients. The study was created on 3/17/2021 and was last edited on 10/18/2022."

Answered by AI

How many locations are conducting this research?

"This study is enrolling at 33 sites, which are situated in and around San Antonio, Houston, and Cypress. Please choose the location most convenient for you to limit travel-related impact on your life if you decide to participate."

Answered by AI

Who else is applying?

What state do they live in?
Texas
North Carolina
South Carolina
How old are they?
18 - 65
What site did they apply to?
GSK Investigational Site
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1
3+

Why did patients apply to this trial?

not being able to breathe is scary! I've had asthma my whole life and am willing to try anything to ease the symptoms. I am worried about being unprepared for a major attack.
PatientReceived no prior treatments

How responsive is this trial?

Typically responds via
Email
Most responsive sites:
  1. GSK Investigational Site: < 48 hours
Average response time
  • < 2 Days
~99 spots leftby Mar 2025